The proposed clinical trial endpoints are the resolution of steatohepatitis without worsening or liver fibrosis and/or improvement in liver fibrosis one stage or greater without worsening of steatohepatitis
Major trials conducted in patients with MASLD have reported prevalence rates of 4246%, 1938%, and 1519% for these symptoms, respectively
Which GLP-1 Medications Are Available
Future trials must ascertain the effect of acute and long-acting insulin on cognition whilst accounting for the influence of individual factors, especially ApoE 4 status
Duration of Treatment Most people can safely use GLP-1 medications for years when properly monitored by their healthcare provider
Retatrutide vs Tirzepatide vs Semaglutide Three compounds dominate current GLP-1-class research conversation: semaglutide (single agonist), tirzepatide (dual agonist), and retatrutide (triple agonist)